Interaktions- und Aggregationsverhalten von Nanopartikeln in Blutserum

Das Interesse an nanopartikulären Wirkstoffsystemen steigt sowohl auf universitärer als auch auf industrieller Seite stetig an. Da diese Formulierungen meist intravenös verabreicht werden, kommt es folglich zu einem direkten Kontakt der Nanopartikel mit den Blutbestandteilen. Adsorption von Plasma Proteinen kann eine deutliche Veränderung der charakteristischen Eigenschaften des Systems induzieren, was dann Wirkungsweise sowie Toxizität stark beinflussen kann. Derzeit findet die Charakterisierung nanopartikulärer Wirkstoffsysteme vor der in vivo Applikation in Pufferlösungen mit physiologischem Salzgehalt statt, es ist jedoch kaum etwas bekannt über deren Wechselwirkungen mit komplexen Proteinmischungen wie sie im Blutserum oder –plasma vorliegen. rnMittels dynamischer Lichtstreuung (DLS) wurde eine einfache und reproduzierbare Methode entwickelt um die Aggregatbildung zwischen Nanopartikeln, Polymeren oder verschiedenen Wirkstoff-Konjugaten in humanem Blutserum zu untersuchen. Die Anwendbarkeit dieser Methode wurde durch Untersuchung verschiedener potentieller Nanotherapeutika (z.B. Polystyrol-Nanokapseln, Liposomen, amphiphile Blockcopolymere und Nanohydrogele) bezüglich ihrer Aggregation in humanem Blutserum mittels DLS gezeigt und teilweise mit aktuellen in vivo Experimenten verglichen. rnDarüber hinaus wurden größeneinheitliche Liposomen, basierend auf Disteraoylphosphatidylcholin, Cholesterol und einem Spermin-Tensid, hergestellt. Die Einkapselung von siRNA ist, je nach Präparationsmethode, mit Einkapselungseffizienzen von 40-75% möglich. Nach detaillierter Charakterisierung der Liposomen wurden diese ebenfalls bezüglich ihres Aggregationsverhaltens in humanem Blutserum untersucht. Unbeladene Liposomen aggregieren nicht mit Komponenten des Serums. Je nach Beladungsprotokoll können aggregierende sowie nicht aggregierende Liposomen-siRNA Komplexe hergestellt werden. rnWeiterhin wurden, zur Identifikation der Aggregation induzierenden Serumkomponenten, verschiedenen Serumsfraktionierungstechniken erfolgreich angewendet. Albumin, IgG, und Lipoproteine (VLDL, LDL) sowie verschiedene Proteinmischungen konnten isoliert und für weitere Aggregationsstudien mittels DLS verwendet werden. Für einige ausgesuchte Systeme konnten die Interaktionspartner identifiziert werden. rnDie Korrelation des Aggregationsverhaltens mit den strukturellen sowie funktionellen Eigenschaften der untersuchten Nanopartikel führt zu dem generellen Ergebnis, dass leicht negativ und leicht positiv bis neutrale Partikel eine geringe Tendenz zur Aggregation in Serum haben. Auch zwitterionische Substanzen zeigen eine hohe Serumstabilität. Hingegen aggregieren stark positiv und negativ geladene Partikel vermehrt.rn

Lichtsammler hinter Glas : Stabilisierung und Funktionalisierung des pflanzlichen Hauptlichtsammelkomplexes (LHCII) durch biomineralische Einbettung in Nanopartikel

Der Haupt-Lichtsammelkomplex des Fotosystems II (LHCII) setzt sich aus einem Proteinanteil und nicht-kovalent gebundenen Pigmenten – 8 Chlorophyll a, 6 Chlorophyll b und 4 Carotinoide - zusammen. Er assembliert in vivo zu einem Trimer, in dem die Monomereinheiten ebenfalls nicht-kovalent miteinander wechselwirken. Die ausgesprochen hohe Farbstoffdichte und die Tatsache, dass der Komplex rekombinant hergestellt werden kann, machen den LHCII zu einem interessanten Kandidaten für technische Anwendungen wie einer Farbstoffsolarzelle. Allerdings muss hierzu seine thermische Stabilität drastisch erhöht werden.rnDer Einschluss von Proteinen/Enzymen in Silikat erhöht deren Stabilität gegenüber Hitze signifikant. LHCII sollte als erster rekombinanter Membranproteinkomplex mittels kovalent verbundener, polykationischen Sequenzen in Silikat eingeschlossen werden. Hierzu wurde der Komplex auf zwei Weisen polykationisch modifiziert: Auf Genebene wurde die Sequenz des R5-Peptids in den N-terminalen Bereich des LHCP-Gens eingeführt und ein Protokoll zur Überexpression, Rekonstitution und Trimerisierung etabliert. Außerdem wurde eine kovalente Modifikation des trimeren LHCII mit dem Arginin-reichen Protamin über heterobifunktionelle Crosslinker entwickelt. Beide resultierenden LHCII-Derivate waren in der Lage, Silikat autogen zu fällen. Die Stabilisierung der so in Silikat präzipitierten Komplexe war jedoch deutlich geringer als bei nicht-modifizierten Komplexen, die durch eine Spermin-induzierte Copräzipitation eingeschlossenen wurden. Dabei zeigte sich, dass für den Anteil der eingebauten Komplexe und das Ausmaß an Stabilisierung die Größe und klare partikuläre Struktur des Silikats entscheidend ist. Kleine Partikel mit einem Durchmesser von etwa 20 nm führten zu einem Einbau von rund 75 % der Komplexe, und mehr als 80 % des Energietransfers innerhalb des Komplexes blieben erhalten, wenn für 24 Stunden bei 50°C inkubiert wurde. Nicht in Silikat eingeschlossene Komplexe verloren bei 50°C ihren Komplex-internen Energietransfer binnen weniger Minuten. Es war dabei unerheblich, ob die Partikelgröße durch die Wahl des Puffers und des entsprechenden pH-Wertes, oder aber durch Variation des Spermin-zu-Kieselsäure-Verhältnisses erreicht wurde. Wurden die polykationisch veränderten Komplexe in solchen Copräzipitationen verwendet, so erhöhte sich der Anteil an eingebauten Komplexen auf über 90 %, jedoch wurde nur bei der R5-modifizierten Variante vergleichbare Ausmaße an Stabilisierung erreicht. Ein noch höherer Anteil an Komplexen wurde in das Silikatpellet eingebaut, wenn LHCII kovalent mit Silanolgruppen modifiziert wurde (95 %); jedoch war das Ausmaß der Stabilisierung wiederum geringer als bei einer Copräzipitation. Die analysierten Fällungssysteme waren außerdem in der Lage, Titandioxid zu fällen, wobei der Komplex in dieses eingebaut wurde. Allerdings muss das Stabilisierungspotential hier noch untersucht werden. Innerhalb eines Silikatpräzipitats aggregierten die Komplexe nicht, zeigten aber einen inter-trimeren Energietransfer, der sehr wahrscheinlich auf einem Förster Resonanz Mechanismus basiert. rnDies und das hohe Maß an Stabilisierung eröffnen neue Möglichkeiten, rekombinanten LHCII in technischen Applikationen als Lichtsammelkomponente zu verwenden.rn

Nanopartículas lipídicas sólidas e vesículas cataniônicas contendo ftalocianina de cloro alumínio aplicadas nos processos fotodinâmicos

O trabalho apresentado foi realizado em duas etapas independentes e baseou-se no estudo de diferentes sistemas nanométricos para viabilizar a aplicação da ftalocianina de cloro alumínio (ClAlPc) na terapia fotodinâmica (TFD) para o tratamento do câncer de pele do tipo melanoma. O fármaco fotossensibilizante (FS) utilizado apresenta propriedades físico-químicas que lhe permitem exercer sua atividade fotodinâmica com excelência, sem a interferência do cromóforo endógeno melanina existente nas células melanocíticas. Para driblar sua elevada hidrofobicidade, ClAlPc foi encapsulada em sistemas nanométricos para administração em meio fisiológico. Inicialmente nanopartículas lipídicas sólidas (NLS) foram desenvolvidas por emulsificação direta, após um estudo de elaboração do diagrama de fases. O compritol foi o lipídio sólido escolhido para compor as NLS, com diferentes concentrações de ClAlPc. Todas as formulações desenvolvidas foram devidamente caracterizadas, com tamanho médio entre 100 e 200 nm, baixa polidispersão, potencial zeta adequadamente negativo (~|30| mV), drug loading de ClAlPc entre 76-94% (com pequena redução após 24 meses) e alta eficiência de encapsulação (E.E.). A morfologia arredondada das nanopartículas foi confirmada por microscopia eletrônica de transmissão e de força atômica. A estabilidade das NLS foi de 24 meses. A avaliação da cristalinidade do lipídio revelou a integração da ClAlPc à matriz lipídica da NLS, presença de estruturas polimórficas e grau de cristalinidade adequado, sem alterações após 24 meses. Nos estudos de difusão in vitro, observou-se que ftalocianina encapsulada nas NLS acumulam-se preferencialmente na epiderme e derme do que no estrato córneo, sem traços de permeação do ativo. Foi confirmado o caráter biocompatível das NLS sobre fibroblastos NIH-3T3. A ftalocianina encapsulada nas NLS não foi tóxica na linhagem de melanoma B16-F10 na ausência de luz, porém, apresentou excelente efeito fototóxico (0,75 ?g mL-1 de ClAlPc nanoencapsulada e irradiação entre 0,5 e 2,0 J cm-2), com redução da viabilidade celular de 87%. O segundo sistema de veiculação estudado foram as vesículas cataniônicas (VesCat), que se formam espontaneamente em água com o tensoativo TriCat 12. A obtenção das vesículas contendo ClAlPc envolve uma etapa adicional, para remoção de solvente orgânico, que foi aprimorada, reduzindo o tempo de produção em 55%. As VesCat/ClAlPc obtidas mantiveram suas propriedades físico-químicas e morfologia arredondada (confirmada por microscopia eletrônica de varredura), drug loading de 47% e alta E.E. Os resultados comprovaram que a aplicação desses dois sistemas nanométricos é altamente eficiente para aplicação da TFD no tratamento do câncer de pele do tipo melanoma ou outras doenças cutâneas, apresentando características favoráveis para avanços nos estudos de fase clínica e pré-clínica.

Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method

The ann of this study was to investigate the incorporation of a model antigen, fluorescently labelled ovalbumin (FITC-OVA), into various colloidal particles including immune stimulating complexes (ISCOMs), liposomes, ring and worm-like micelles, lamellae and lipidic/layered structures that are formed from various combinations of the triterpene saponin Quil A, cholesterol and phosphatidylethanolamine (PE) following hydration of PE/cholesterol lipid films with aqueous Solutions of Quil A. Colloidal dispersions of these three components were also prepared by the dialysis method for comparison. FITC-OVA was conjugated with palmitic acid (P) and PE to produce P-FITC-OVA and PE-FITC-OVA, respectively. Both P-FITC-OVA and PE-FITC-OVA could be incorporated in all colloidal structures whereas FITC-OVA was incorporated only into liposomes. The incorporation of PE-FITC-OVA into all colloidal structures was significantly higher than P-FITC-OVA (P < 0.05). The degree of incorporation of protein was in the order: ring and worm-like micelles < liposomes and lipidic/layered structures < ISCOMs and lamellae. The incorporation of protein into the various particles prepared by the lipid film hydration method was similar to those for colloidal particles prepared by the dialysis method (provided both methods lead to the formation of the same colloidal structures). In the case of different colloidal structures arising due to the preparation method, differences in encapsulation efficiency were found (P < 0.05) for formulations with the same polar lipid composition. This study demonstrates that the various colloidal particles formed as a result of hydrating PE/cholesterol lipid films with different amounts of Quil A are capable of incorporating antigen, provided it is amphipathic. Some of these colloidal particles may be used as effective vaccine delivery systems. (C) 2004 Elsevier B.V. All rights reserved.

The effect of complexation on characteristics and drug release from PLGA microspheres loaded by cyclosporine-cyclodextrin complex

The purpose of this study was to evaluate the effect of cyclosporine (CyA)-cyclodextrin (CD) complex incorporated within PLGA inicrospheres on microsphere characteristics, with particular emphasis on drug release kinetics. For this purpose, microspheres encapsulated with CyA and those loaded by CyA-CD complex were prepared by solvent evaporation and multiple emulsification solvent evaporation methods, respectively. Morphology, size, encapsulation efficiency and drug release pattern from microspheres were evaluated. Also, physicochemical properties of drug inside microspheres were characterized by differential scanning calorimetry (DSC) and infrared spectroscopy (IR) studies. Scanning electron microscopy (SEM) studies showed that microspheres encapsulated with CyA had islands on the microsphere surface but the islands were not seen on the surface of microspheres loaded by complex. Size range varied from 1 to 25 mu m for CyA encapsulated microspheres and 1 to 50 mu m for complex loaded microspheres. The release of CyA was biphasic with an initial more rapid release phase followed by a slower phase but drug release was twice as fast for complex loaded microspheres. IR studies did not indicate any chemical interaction between the components of microspheres and DSC thermograms revealed that CyA was present either in its amorphous state in microspheres or the presence of CyA as an inclusion complex within microspheres loaded by complex. In conclusion, using CyA as an inclusion complex with CD within microspheres can affect microsphere characteristics and drug release and it is possible to modify microsphere properties like drug release by incorporating CDs as complexing agents.

Incorporation and release of macromolecules from biodegradable polymer vehicles

The initial objective of this work was to evaluate and introduce fabrication techniques based on W/0/W double emulsion and 0/W single emulsion systems with solvent evaporation for the incorporation of a surrogate macromolecule (BSA) into microspheres and microcapsules fabricated using P(HB-HV}, PEA and their blends. Biodegradation, expressed as changes in the gross and ultrastructural morphology of BSA loaded microparticulates with time was monitored using SEM concomitant with BSA release. Spherical microparticulates were successfully fabricated using both the W/0/W and 0/W emulsion systems. Both microspheres and microcapsules released BSA over a period of 24 to 26 days. BSA release from P(HB-HV)20% PCL 11 microcapsules increased steadily with time, while BSA release from all other microparticulates was characterised by an initial lag phase followed by exponential release lasting 6-11 days. Microcapsules were found to biodegrade more rapidly than microspheres fabricated from the same polymer. The incubation of microparticulates in newborn calf serum; synthetic gastric juice and pancreatin solution showed that microspheres and microcapsules were susceptible to enzymatic biodegradation. The in vitro incubation of microparticulates in Hank's buffer demonstrated limited biodegradation of microspheres and microcapsules by simple chemical hydrolysis. BSA release was thought to ocurr as a result of the macromolecule diffusing through either inherent micropores or via pores and channels generated in situ by previously dissolved BSA. However, in all cases, irrespective of percentage loading or fabrication polymer, low encapsulation efficiencies were obtained with W/0/W and 0/W techniques (4.2±0.9%- 15.5±0.5%,n=3), thus restricting the use of these techniques for the generation of microparticulate sustained drug delivery devices. In order to overcome this low encapsulation efficiency, a W/0 single emulsion technique was developed and evaluated in an attempt to minimise the loss of the macromolecule into the continuous aqueous phase and increase encapsulation efficiency. Poly(lactide-co-glycolide) [PLCG] 75:25 and 50:50, PEA alone and PEA blended with PLCG 50:50 to accelerate biodegradation, were used to microencapsulate the water soluble antibiotic vancomycin, a putative replacement for gentamicin in the control of bacterial infection in orthopaedic surgery especially during total hip replacement. Spherical microspheres (17.39±6.89~m,n=74-56.5±13.8~m,n=70) were successfully fabricated with vancomycin loadings of 10, 25 and 50%, regardless of the polymer blend used. All microspheres remained structurally intact over the period of vancomycin release and exhibited high percentage yields( 40. 75±2 .86%- 97.16±4.3%,n=3)and encapsulation efficiencies (47.75±9.0%- 96.74±13.2%,n=12). PLCG 75:25 microspheres with a vancomycin loading of 50% were judged to be the most useful since they had an encapsulation efficiency of 96.74+13.2%, n=12 and sustained therapeutically significant vancomycin release (15-25μg/ml) for up to 26 days. This work has provided the means for the fabrication of a spectrum of prototype biodegradable microparticulates, whose biodegradation has been characterised in physiological media and which have the potential for the sustained delivery of therapeutically useful macromolecules including water soluble antibiotics for orthopaedic applications.

Novel formulations for antigen delivery using biodegradable polymers: new approaches for the use of new and established adjuvants

The use of immunological adjuvants has been established since 1924 and ever since many candidates have been extensively researched in vaccine development. The controlled release of vaccine is another area of biotechnology research, which is advancing rapidly with great potential and success. Encapsulation of peptide and protein drugs within biodegradable microspheres has been amongst the most successful of approaches within the past decade. The present studies have focused on combining the advantages of microsphere delivery systems composed of biodegradable polylactide (PLLA) and polylactide-co-glycolide (PLGA) polymers with that of safe and effective adjuvants. The research efforts were directed to the development of single-dose delivery vehicles which, can be manufactured easily, safely, under mild and favourable conditions to the encapsulated antigens. In pursuing this objective non ionic block copolymers (NIBCs) (Pluronics@ LI01 and L121) were incorporated within poly-dl-lactide (PDLA) micorospheres prepared with emulsification-diffusion method. LI0I and L121 served both as adjuvants and stabilising agents within these vaccine delivery vehicles. These formulations encapsulating the model antigens lysozyme, ovalbumin (OVA) and diphtheria toxoid (DT) resulted in high entrapment efficiency (99%), yield (96.7%) and elicited high and sustained immune response (IgG titres up to 9427) after one single administration over nine months. The structural integrity of the antigens was preserved within these formulations. In evaluating new approaches for the use of well-established adjuvants such as alum, these particles were incorporated within PLLA and PLGA microspheres at much lesser quantities (5-10 times lower) than those contained within conventional alum-adsorbed vaccines. These studies focused on the incorporation of the clinically relevant tetanus toxoid (TT) antigen within biodegradable microspheres. The encapsulation of both alum particles and TT antigen within these micropheres resulted in preparations with high encapsulation efficiency (95%) and yield (91.2%). The immune response to these particles was also investigated to evaluate the secretion of serum IgG, IgG1, IgG2a and IgG2b after a single administration of these vaccines. The Splenic cells proliferation was also investigated as an indication for the induction of cell mediated immunity. These particles resulted in high and sustained immune response over a period of 14 months. The stability of TT within particles was also investigated under dry storage over a period of several months. NIBC microspheres were also investigated as potential DNA vaccine delivery systems using hepatitis B plasmid. These particles resulted in micro spheres of 3-5 μm diameter and were shown to preserve the integrity of the encapsulated (27.7% entrapment efficiency) hepatitis B plasmid.

Poly lactic-co-glycolic acid controlled delivery of Disulfiram to target liver cancer stem-like cells

Disulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or Sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.

Obtenção e caracterização de sistemas particulados de quitosana para liberação gástrica de amoxicilina

The infection caused by Helicobacter pylori (H. pylori) is associated with gastroduodenal inflammation can lead to the development of gastritis, gastric or duodenal ulcer and gastric cancer (type 1 carcinogen for stomach cancer). Amoxicillin is used as first-line therapy in the treatment of H. pylori associated to metronidazole or clarithromycin, and a proton pump inhibitor. However, the scheme is not fully effective due to inadequate accumulation of antibiotics in gastric tissue, inadequate efficacy of ecological niche of H. pylori, and other factors. In this context, this study aimed to obtaining and characterization of particulate systems gastrorretentivos chitosan - amoxicillin aiming its use for treatment of H. pylori infections. The particles were obtained by the coacervation method / precipitation using sodium sulfate as precipitating agent and crosslinking and two techniques: addition of amoxicillin during preparation in a single step and the sorption particles prior to amoxycillin prepared by coacervation / precipitation and spray drying. The physicochemical characterization of the particles was performed by SEM, FTIR, DSC, TG and XRD. The in vitro release profile of amoxycillin free and incorporated in the particles was obtained in 0.1 N HCl (pH = 1.2). The particles have higher encapsulation efficiency to 80% spherical shape with interconnected particles or adhered to each other, the nanometric diameter to the systems obtained by coacervation / precipitation and fine for the particles obtained by spray drying. The characterization by FTIR, DSC and XRD showed that the drug was incorporated into the nanoparticles dispersed in the polymeric matrix. Thermal analysis (TG and DSC) indicated that encapsulation provides greater heat stability to the drug. Amoxicillin encapsulated in nanoparticles had slower release compared to free drug. The particles showed release profile with a faster initial stage (burst effect) reaching a maximum at 30 minutes 35% of amoxicillin for the system in 1: 1 ratio relative to the polymer and 80% for the system in the ratio 2: 1. Although simple and provide high encapsulation efficiency of amoxicillin, the process of coacervation, precipitation in one step using sodium sulfate as precipitant / cross-linker must be optimized in order to adjust the release kinetics according to the intended application.

Ruptura celular, extração e encapsulamento de Astaxantina de Haematococcus pluvialis (Volvocales, Chlorophyta)

O interesse na produção de astaxantina de fontes naturais vem aumentando significativamente, devido principalmente à sua capacidade como potente agente antioxidante. Na obtenção da astaxantina por via biotecnológica, a microalga Haematococcus pluvialis é um dos micro-organismos industrialmente mais interessantes. Entretanto, como a maioria dos carotenoides, a astaxantina é uma molécula altamente insaturada que pode ser facilmente degradada por processos térmicos. Em função desta instabilidade, uma possibilidade que se abre, a fim de proteger sua atividade biológica de fatores ambientais e reforçar a sua estabilidade física, é o encapsulamento. Neste sentido, este trabalho vem contribuir em inovações relacionadas ao desenvolvimento de tecnologia para ruptura celular, extração e nanoencapsulamento de astaxantina produzida por via biotecnológica, mais especificamente de astaxantina obtida através do cultivo de H. pluvialis. Neste estudo, os cultivos foram realizados em meio BBM e acetato de sódio e conduzidos a temperatura constante de 25±1 ºC em fotobiorreatores de 1 L com aeração por borbulhamento de ar de 300 mL.min-1 , agitação manual diária e sob iluminância constante de 444 µmol fótons.m-2 s -1 durante 15 dias, sendo inoculados com suspensão de microalgas previamente preparada, na proporção de 10%, e pH ajustado em 7,0. A biomassa foi recuperada dos cultivos por centrifugação e seca a 35 °C por 48 h. Em seguida, foram empregadas diferentes técnicas de ruptura celular (química, mecânica e enzimática). Após a ruptura, foi realizada a extração dos carotenoides e a quantificação dos carotenoides totais (µg.g-1 ) e da extratibilidade (%). Entre os solventes testados no método de ruptura química, o diclorometano foi o selecionado para a extração dos pigmentos carotenoides. Dentre as técnicas mecânicas de ruptura celular, a maceração da biomassa congelada com terra diatomácea resultou na maior extratibilidade e carotenoides totais (66,01% e 972,35 μg.g-1 ). A melhor condição de lise da parede celular de H. pluvialis, utilizando o preparado enzimático Glucanex® , ocorreu em pH do meio reacional de 4,5 a 55 ºC, com atividade inicial de β-1,3-glucanase de 0,6 U.mL-1 e um tempo de reação de 30 min, alcançando-se 17,73% de atividade lítica relativa. Nestas condições, com a reação enzimática assistida por ultrassom sem congelamento prévio da biomassa, atingiu-se 83,90% e 1235,89 µg.g -1 , respectivamente, para extratibilidade e carotenoides totais. Dentre as técnicas combinadas testadas, a maceração com terra diatomácea associada à lise enzimática apresentou valores de extratibilidade e carotenoides totais de, respectivamente, 93,83% e 1382,12 µg.g-1 . No encapsulamento do extrato contendo astaxantina obtido por lise enzimática associada por ultrassom, envolvendo a coprecipitação com PHBV (poli(3-hidroxibutirato-cohidroxivalerato)) em fluidos supercríticos, o aumento da pressão tendeu a reduzir o diâmetro da partícula formada, enquanto que o aumento da relação biomassa contendo astaxantina:diclorometano usada na etapa de extração incrementou o percentual de encapsulamento e a eficiência de encapsulamento para ambas pressões testadas (80 e 100 bar). Os maiores valores de percentual de encapsulamento (17,06%) e eficiência de encapsulamento (51,21%) foram obtidos nas condições de 80 bar e relação biomassa:diclorometano de 10 mg.mL -1 . Nestas condições, o diâmetro médio de partícula foi de 0,228 µm. Com base nos resultados obtidos, técnicas para a obtenção de astaxantina de H. pluvialis e seu encapsulamento foram desenvolvidas com sucesso, podendo ser extendidas a outros produtos intracelulares de microalgas.

Sustained release of TGF-β1 from biodegradable microparticles prepared by a new green process in CO2 medium

International audience

Obtenção de extratos de agaricus bisporus com ergosterol para incorporação em iogurtes e procedimentos de microencapsulação

Além de ser o cogumelo mais consumido no mundo, Agaricus bisporus é um dos cogumelos mais ricos em ergosterol, representando esta molécula quase 90% da sua fração de esteróis. Vários estudos têm atribuído ao ergosterol diferentes bioatividades, incluindo efeitos hipocolesterolémicos semelhantes aos exibidos pelos fitoesteróis. Isto torna o ergosterol uma molécula interessante para ser estudada como composto nutracêutico. Assim, este trabalho teve como objetivo avaliar o potencial de utilização dos extratos de A. bisporus ricos em ergosterol na produção de bebidas lácteas funcionais. Para o efeito, foram realizados testes de incorporação do extrato e do ergosterol puro em iogurtes que se compararam com bebidas lácteas funcionais comerciais (aditivadas com fitoesteróis). As amostras de A. bisporus foram submetidas a uma extração assistida por ultrassons e os extratos obtidos (IEXT), bem como a molécula de ergosterol em diferentes concentrações (IERG1 e IERG2), foram incorporados em iogurtes, e comparadas com amostras controlo (amostras de iogurte sem aditivos) (ICN) e iogurtes comerciais contendo fitoesteróis (ICP). Todas as amostras foram analisadas imediatamente após a incorporação (T0), e após sete dias de armazenagem a 4°C (T1), em relação aos parâmetros nutricionais, atividade antioxidante e propriedades citotóxicas em linhas celulares tumorais humanas e numa cultura primária de células de fígado de porco (não tumoral) para avaliação da toxicidade. O teor de ergosterol incorporado na forma pura, ou presente nos extratos, foi monitorizado por HPLC-UV. Adicionalmente, foi realizado um estudo de microencapsulação utilizando a técnica de coacervação, tendo o quitosano e o isolado proteico de soro como materiais encapsulantes. Num ensaio preliminar determinou-se o pH conducente a um maior rendimento de encapsulação e, seguidamente, verificou-se a influência da razão proteína:quitosano (P/Q) e da temperatura utilizada, no rendimento de encapsulação (Y1), na eficiência de encapsulação (Y2) e na carga (teor de ergosterol nas microesferas) (Y3). Posteriormente, o estudo foi realizado baseando-se nas melhores condições para encapsular ergosterol, sendo também avaliadas as respostas Y1, Y2 e Y3. Além de ser o cogumelo mais consumido no mundo, Agaricus bisporus é um dos cogumelos mais ricos em ergosterol, representando esta molécula quase 90% da sua fração de esteróis. Vários estudos têm atribuído ao ergosterol diferentes bioatividades, incluindo efeitos hipocolesterolémicos semelhantes aos exibidos pelos fitoesteróis. Isto torna o ergosterol uma molécula interessante para ser estudada como composto nutracêutico. Assim, este trabalho teve como objetivo avaliar o potencial de utilização dos extratos de A. bisporus ricos em ergosterol na produção de bebidas lácteas funcionais. Para o efeito, foram realizados testes de incorporação do extrato e do ergosterol puro em iogurtes que se compararam com bebidas lácteas funcionais comerciais (aditivadas com fitoesteróis). As amostras de A. bisporus foram submetidas a uma extração assistida por ultrassons e os extratos obtidos (IEXT), bem como a molécula de ergosterol em diferentes concentrações (IERG1 e IERG2), foram incorporados em iogurtes, e comparadas com amostras controlo (amostras de iogurte sem aditivos) (ICN) e iogurtes comerciais contendo fitoesteróis (ICP). Todas as amostras foram analisadas imediatamente após a incorporação (T0), e após sete dias de armazenagem a 4°C (T1), em relação aos parâmetros nutricionais, atividade antioxidante e propriedades citotóxicas em linhas celulares tumorais humanas e numa cultura primária de células de fígado de porco (não tumoral) para avaliação da toxicidade. O teor de ergosterol incorporado na forma pura, ou presente nos extratos, foi monitorizado por HPLC-UV. Adicionalmente, foi realizado um estudo de microencapsulação utilizando a técnica de coacervação, tendo o quitosano e o isolado proteico de soro como materiais encapsulantes. Num ensaio preliminar determinou-se o pH conducente a um maior rendimento de encapsulação e, seguidamente, verificou-se a influência da razão proteína:quitosano (P/Q) e da temperatura utilizada, no rendimento de encapsulação (Y1), na eficiência de encapsulação (Y2) e na carga (teor de ergosterol nas microesferas) (Y3). Posteriormente, o estudo foi realizado baseando-se nas melhores condições para encapsular ergosterol, sendo também avaliadas as respostas Y1, Y2 e Y3. As bebidas funcionalizadas com o extrato (IEXT) e com ergosterol na mesma concentração existente no extrato (IERG1) revelaram uma atividade antioxidante similar às bebidas comerciais com fitoesteróis. No entanto, as bebidas com ergosterol na mesma concentração do extrato de A. bisporus e de fitoesteróis (IERG2) revelaram uma atividade antioxidante superior. Além disso, apenas IEXT, IERG1 e IERG2 apresentaram um aumento na atividade antioxidante de T0 para T1, com destaque para a atividade exibida por IERG2, significando que o ergosterol e os extratos foram capazes de proteger a bebida láctea da oxidação, aumentando a vida de prateleira do produto. IERG2 foi a amostra que revelou a maior citotoxicidade para as linhas celulares tumorais, enquanto as bebidas com fitoesteróis mostraram a menor atividade, sem diferenças significativas entre T0 e T1. Os estudos de microencapsulação revelaram ainda que a técnica de coacervação permite obter cápsulas de distintos tamanhos e que as condições ótimas do processo ocorrem a pH 5,5, com temperatura de 55ºC e razão P/Q de 0,5, com um menor rendimento de encapsulação, mas com uma maior carga em ergosterol. Este trabalho contribuiu para o estudo do potencial da utilização de extratos de A. bisporus com ergosterol no desenvolvimento de novas bebidas funcionais. Constituiu um primeiro passo que necessita de estudos subsequentes relacionados com a avaliação da viabilidade da sua utilização ao nível industrial e demonstração clara da sua bioatividade in vivo.

Antimicrobial effect of polymeric biomaterials for bone infection treatment

Dissertação de mestrado em Bioquímica, apresentada à Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, 2016.

Utilization of free and microencapsulated Rosmarinus oficinalis L. extracts as bioactives ingredientes for new functional foods developmen

Currently, many consumers search for food with functional characteristics beyond their nutritional properties. Thus, the concept of functional food becomes a hot topic, allowing the obtaining of health benefits, including disease prevention. In this context, plants are recognized as sources of a wide range of bioactives, mainly phenolic compounds. In particular, the Rosmarinus officina/is L., commonly referred as rosemary, has several phenolic compounds with different bioactive properties such as antioxidant, antiinflammatory and antimicrobial activities, among others [!]. Hence, this plant has great potential for incorporation into foods in order to confer bioactivity to the final products. However, it should be highlighted that the bioactive compounds if exposed to adverse environments, for example: light, moisture, extreme pH, storage, food processing conditions, can be degraded leading to the consequent loss of bioactivity [2]. The microencapsulation is an alternative to overcome this problematic of bioactive compounds, as also to ensure controlled release, or target deliver to a specific site [3]. In this work, lyophilized rosemary aqueous extract prepared by in:'usion was used as a functional ingredient for cottage cheeses, after proving that it possesses, both higher content in phenolic compounds and higher antioxidant activity, comparatively with the corresponding hydroethanolic extract. The rosemary aqueous extract revealed, for example, a DPPH scavenging activity with an EC50 value of 73.44±0.54j!g/mL and presented as main phenolic compound the caffeic acid dimer, commonly named as rosmarinic acid. For the functionalized cottage cheeses, a decrease of bioactivity was observed after seven days under storage in fridge, when the extracts were incorporated in its free form. Therefore, to preserve the antioxidant activity, the rosemary aqueous extract was efficiently microencapsulated by using an atomization/coagulation technique and alginate as the matrix material and thereafter incorporated into the cottage cheeses. The final microspheres showed a size, estimated by OM using a magnification of I OOx, ranging between 51.1 and 122.6 J!m and an encapsulation efficiency, estimated through an indirect method, approaching 100%. Overall, the introduction of both free and microencapsulated extracts did not change the nutritional value of cottage cheeses, providing bioactivity that was more preserved with microencapsulated extracts putting in evidence the importance of using microencapsulation to develop effective functional foods.

Micoencapsulation of bioactive plant extracts: a tool to functionalize cottage cheeses

Foeniculum vulgare Mill. (fennel) and Matricaria recutita L. (chamomile) are two examples of plants with reported antioxidant and antimicrobial properties, which can be related with their composition in phenolic compounds [1,2]. Furthermore, according to previous results of our research group, the direct incorporation of the aqueous extracts showed capacity to maintain the nutritional properties of the cottage cheeses, up to 7 days of storage, while improving the antioxidant potential. However, after 14 days, a decrease in the antioxidant properties was observed [1,2], which can be related with factors such as light, moisture, temperature and pH, that can cause bioactive compounds degradation. Therefore, the aim of the present study was to prepare microcapsules with the aqueous extracts of fennel and chamomile for incorporation in cottage cheese samples, in order to protect the bioactive molecules present in the extracts, such as phenolic compounds, and prevent the decrease of the antioxidant activity observed after the 14 days period. The microspheres were prepared using an atomization/coagulation technique. Sodium alginate was used as the matrix material to produce the microspheres that were characterized through optical microscopy (OM), during and after atomization, for inspecting morphology. The encapsulation efficiency (EE) was determined by HPLC-DAD by an indirect method by analysing the coagulation solution. FTIR was also used to attest the presence of the extract inside of the alginate matrix. These microencapsulated extracts were incorporated in cottage cheese samples that were further characterized in terms of nutritional properties and antioxidant potential right after incorporation, and after 7 and 14 days of storage at 4•c. The EE was estimated as -100% and the FTIR analysis confirmed the presence of the extracts inside the microspheres. The results showed that the incorporation of the microencapsulated extracts did not cause changes in the nutritional value of cottage cheeses (through a comparison with control samples without extracts). The predominant fatty acids were palmitic (C16:0) and oleic (CI8:0) acids. The order of abundance of fatty acids was as follows: saturated fatty acids (SF A)> monounsaturatcd fatty acids (MUF A)> polyunsaturated fatty acids (PUF A). Regarding free sugars, lactose was the only sugar identified and quantified in all samples. Regarding the antioxidant activity, the samples functionalized with the microencapsulated extracts showed a higher preservation of this property even after the 7th day of storage. Overall, the incorporation of the protected plant extracts in dairy foods can be a strategy to provide health benefits to consumers.